<DOC>
	<DOCNO>NCT01091727</DOCNO>
	<brief_summary>This prospective , multicentre ( 7 site ) , randomize , double-blind , study compare intravesical injection BOTOX placebo 56 subject NDO secondary spinal cord injury multiple sclerosis . Study subject randomize one follow two treatment group : Group 1 n=28 BOTOX - 300U Group 2 n=28 Placebo BOTOX ( saline ) All study subject receive one injection cycle ( BOTOX 300U Placebo ) Visit 2 ( Treatment , Day 0 ) per Supplement III . The study duration approximately 61 week consist Pre-Treatment Evaluation , Treatment/Randomization Visit ( Visit 2 , Day 0 ) , Telephone Follow-ups 1 , 3 4 week post-treatment , Follow-up Visits 6 , 24 36 week ( Visits 3 5 ) . At Week 36 , subject offer open-label BOTOX 300U follow additional 6 month , return evaluation Weeks 48 60 .</brief_summary>
	<brief_title>Intravesical Injection Botulinum Toxin A Versus Saline Neurogenic Detrusor Overactivity</brief_title>
	<detailed_description>This prospective , multicentre ( 7 site ) , randomize , double-blind , study compare intravesical injection BOTOX placebo 56 subject NDO secondary spinal cord injury multiple sclerosis . Study subject randomize one follow two treatment group : Group 1 n=28 BOTOX - 300U Group 2 n=28 Placebo BOTOX ( saline ) All study subject receive one injection cycle ( BOTOX 300U Placebo ) Visit 2 ( Treatment , Day 0 ) per Supplement III . The study duration approximately 61 week consist Pre-Treatment Evaluation , Treatment/Randomization Visit ( Visit 2 , Day 0 ) , Telephone Follow-ups 1 , 3 4 week post-treatment , Follow-up Visits 6 , 24 36 week ( Visits 3 5 ) . At Week 36 , subject offer open-label BOTOX 300U follow additional 6 month , return evaluation Weeks 48 60 .</detailed_description>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Inclusion Criteria 1 . Outpatient , male female subject , race , 18 75 year age . Female subject childbearing potential must negative urine pregnancy test result day Treatment ( Visit 2 ) practice reliable method contraception . 2 . Subjects neurogenic bladder detrusor overactivity secondary either spinal cord injury multiple sclerosis . 3 . Subjects urinary incontinence ( minimum one occurrence per day ) despite current treatment . 4 . Subjects serum creatinine within normal limit normal renal function . 5 . Subjects stable dose ( minimum one month ) concomitant medication NDO . 6 . Subjects able understand requirement study , include complete questionnaire sign Informed Consent . Exclusion Criteria 1 . Female subject pregnant ( positive urine pregnancy test ) , plan become pregnant study period , infant breastfeeding , childbearing potential practicing reliable method birth control . 2 . Subjects history transurethral sphincterotomy , bladder neck prostatic resection , previous bladder surgery include myomectomy augmentation cystoplasty . 3 . Subjects chronic indwell catheter . 4 . Subjects medical condition may increase risk exposure botulinum toxin include diagnose Myasthenia Gravis , EatonLambert Syndrome , Amyotrophic Lateral Sclerosis disease might interfere neuromuscular function . 5 . Subjects allergy sensitivity component BOTOXÂ® ( Section 5.2 ) . 6 . Subjects unable discontinue agent might interfere neuromuscular function ( i.e. , aminoglycoside antibiotic , curarelike agent , etc. ) . 7 . Subjects , opinion Investigator , unstable stable multiple sclerosis . 8 . Subjects know , uncontrolled systemic disease . 9 . Subjects evidence recent alcohol/drug abuse . 10 . Subjects , opinion Investigator , significant condition situation may put subject significant risk , confound study result , interfere significantly subject 's participation study . 11 . Subjects history poor cooperation , noncompliance , unreliability . 12 . Subjects currently participate investigational drug study participate investigational drug study within 30 day Baseline Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Neurogenic</keyword>
	<keyword>Detrusor</keyword>
	<keyword>Overactive</keyword>
	<keyword>Overactivity</keyword>
	<keyword>Bladder</keyword>
	<keyword>Spinal</keyword>
	<keyword>Cord</keyword>
	<keyword>Injury</keyword>
</DOC>